| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Antifungal Agents | 29 | 2021 | 1828 | 4.18 | Why? |
| Mucorales | 6 | 2021 | 92 | 3.74 | Why? |
| Mucormycosis | 12 | 2021 | 832 | 2.98 | Why? |
| Voriconazole | 9 | 2020 | 206 | 2.75 | Why? |
| Aspergillosis, Allergic Bronchopulmonary | 5 | 2019 | 38 | 2.49 | Why? |
| Candida | 9 | 2019 | 425 | 2.26 | Why? |
| Drug Resistance, Fungal | 7 | 2019 | 191 | 2.08 | Why? |
| Mycoses | 9 | 2019 | 589 | 1.99 | Why? |
| Histoplasma | 2 | 2019 | 42 | 1.49 | Why? |
| Histoplasmosis | 2 | 2019 | 83 | 1.38 | Why? |
| Amphotericin B | 6 | 2020 | 256 | 1.19 | Why? |
| Aspergillus | 4 | 2019 | 347 | 1.18 | Why? |
| Aspergillus flavus | 5 | 2019 | 51 | 1.08 | Why? |
| Aspergillus fumigatus | 6 | 2019 | 239 | 1.07 | Why? |
| Aspergillosis | 4 | 2019 | 264 | 0.99 | Why? |
| Candida albicans | 3 | 2018 | 217 | 0.97 | Why? |
| Itraconazole | 3 | 2018 | 135 | 0.96 | Why? |
| Mannans | 5 | 2019 | 218 | 0.96 | Why? |
| Antigens, Fungal | 4 | 2019 | 106 | 0.96 | Why? |
| Candidiasis | 5 | 2019 | 334 | 0.94 | Why? |
| Fungi | 5 | 2018 | 471 | 0.87 | Why? |
| Invasive Fungal Infections | 4 | 2018 | 274 | 0.86 | Why? |
| Zygomycosis | 1 | 2019 | 8 | 0.80 | Why? |
| Fungemia | 2 | 2018 | 86 | 0.80 | Why? |
| Invasive Pulmonary Aspergillosis | 4 | 2021 | 634 | 0.78 | Why? |
| Biofilms | 3 | 2019 | 304 | 0.77 | Why? |
| Squalene Monooxygenase | 1 | 2018 | 1 | 0.76 | Why? |
| Allylamine | 1 | 2018 | 3 | 0.76 | Why? |
| Trichophyton | 1 | 2018 | 10 | 0.75 | Why? |
| ATP-Binding Cassette Transporters | 1 | 2018 | 48 | 0.74 | Why? |
| Deoxycholic Acid | 1 | 2018 | 17 | 0.73 | Why? |
| Pneumocystis Infections | 1 | 2017 | 10 | 0.73 | Why? |
| Prednisolone | 3 | 2019 | 443 | 0.73 | Why? |
| Immunoglobulin E | 8 | 2019 | 557 | 0.69 | Why? |
| Brain Abscess | 1 | 2017 | 50 | 0.68 | Why? |
| Asthma | 6 | 2019 | 4383 | 0.68 | Why? |
| India | 20 | 2021 | 11875 | 0.68 | Why? |
| beta-Glucans | 2 | 2018 | 176 | 0.67 | Why? |
| Drug Resistance, Multiple, Fungal | 1 | 2017 | 45 | 0.67 | Why? |
| Ascomycota | 1 | 2017 | 71 | 0.66 | Why? |
| Immunoenzyme Techniques | 1 | 2019 | 448 | 0.64 | Why? |
| Benzamides | 1 | 2019 | 421 | 0.64 | Why? |
| Urine | 1 | 2019 | 469 | 0.62 | Why? |
| Microbial Sensitivity Tests | 11 | 2019 | 2886 | 0.62 | Why? |
| Triazoles | 2 | 2020 | 440 | 0.62 | Why? |
| Sinusitis | 3 | 2018 | 649 | 0.60 | Why? |
| Pneumocystis carinii | 1 | 2017 | 205 | 0.59 | Why? |
| Fluconazole | 5 | 2019 | 145 | 0.58 | Why? |
| Nasal Cavity | 2 | 2019 | 909 | 0.58 | Why? |
| Hypersensitivity, Immediate | 1 | 2017 | 134 | 0.58 | Why? |
| Saccharomyces cerevisiae | 1 | 2017 | 339 | 0.57 | Why? |
| Candida tropicalis | 3 | 2019 | 21 | 0.56 | Why? |
| Galactose | 5 | 2019 | 201 | 0.49 | Why? |
| Tertiary Care Centers | 8 | 2021 | 8248 | 0.49 | Why? |
| Cystic Fibrosis | 2 | 2018 | 1104 | 0.45 | Why? |
| Diagnostic Tests, Routine | 3 | 2019 | 2643 | 0.44 | Why? |
| Antibodies, Fungal | 3 | 2019 | 49 | 0.42 | Why? |
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 3 | 2019 | 449 | 0.41 | Why? |
| Pulmonary Aspergillosis | 3 | 2020 | 408 | 0.40 | Why? |
| Candidemia | 3 | 2019 | 353 | 0.38 | Why? |
| Pythiosis | 2 | 2018 | 3 | 0.38 | Why? |
| Pythium | 2 | 2018 | 3 | 0.38 | Why? |
| Probiotics | 1 | 2017 | 694 | 0.38 | Why? |
| Amplified Fragment Length Polymorphism Analysis | 2 | 2018 | 11 | 0.37 | Why? |
| Membrane Glycoproteins | 1 | 2017 | 2273 | 0.36 | Why? |
| Bacillus subtilis | 2 | 2018 | 34 | 0.36 | Why? |
| Fungal Proteins | 2 | 2018 | 133 | 0.33 | Why? |
| Gastrointestinal Diseases | 2 | 2018 | 2580 | 0.31 | Why? |
| Peptides, Cyclic | 2 | 2018 | 223 | 0.31 | Why? |
| Microbiological Techniques | 2 | 2018 | 232 | 0.30 | Why? |
| Vitamin D | 2 | 2019 | 2904 | 0.30 | Why? |
| Carrier State | 1 | 2017 | 2100 | 0.30 | Why? |
| Immunocompromised Host | 3 | 2018 | 5150 | 0.30 | Why? |
| Genomics | 1 | 2017 | 3118 | 0.29 | Why? |
| Molecular Diagnostic Techniques | 2 | 2019 | 4239 | 0.28 | Why? |
| Respiratory System | 1 | 2017 | 3213 | 0.28 | Why? |
| Mycological Typing Techniques | 3 | 2019 | 38 | 0.28 | Why? |
| Vitamin D Deficiency | 1 | 2018 | 1782 | 0.27 | Why? |
| Lung Diseases | 1 | 2017 | 2361 | 0.26 | Why? |
| Smoking | 1 | 2017 | 3358 | 0.25 | Why? |
| DNA, Fungal | 3 | 2018 | 95 | 0.25 | Why? |
| Glucocorticoids | 2 | 2021 | 4431 | 0.25 | Why? |
| Skin Tests | 3 | 2019 | 229 | 0.23 | Why? |
| Male | 37 | 2021 | 367725 | 0.23 | Why? |
| Mycology | 2 | 2018 | 37 | 0.23 | Why? |
| Zinc Compounds | 1 | 2021 | 62 | 0.22 | Why? |
| Adult | 25 | 2021 | 244371 | 0.22 | Why? |
| Treatment Outcome | 10 | 2021 | 51732 | 0.22 | Why? |
| Disease Management | 1 | 2019 | 6841 | 0.21 | Why? |
| Azoles | 2 | 2020 | 185 | 0.21 | Why? |
| Humans | 61 | 2021 | 930598 | 0.20 | Why? |
| RNA, Ribosomal | 2 | 2017 | 39 | 0.20 | Why? |
| Candida parapsilosis | 1 | 2019 | 34 | 0.20 | Why? |
| Conidiobolus | 1 | 2019 | 2 | 0.20 | Why? |
| Isotope Labeling | 1 | 2019 | 39 | 0.20 | Why? |
| Fasciitis, Necrotizing | 1 | 2020 | 56 | 0.20 | Why? |
| Sterol 14-Demethylase | 1 | 2018 | 8 | 0.20 | Why? |
| Consensus Development Conferences as Topic | 1 | 2019 | 93 | 0.19 | Why? |
| Echinocandins | 2 | 2017 | 139 | 0.19 | Why? |
| Pulmonary Disease, Chronic Obstructive | 1 | 2017 | 3832 | 0.19 | Why? |
| Female | 32 | 2021 | 380317 | 0.19 | Why? |
| Arthrodermataceae | 1 | 2018 | 8 | 0.19 | Why? |
| Yeasts | 1 | 2018 | 50 | 0.19 | Why? |
| Young Adult | 12 | 2020 | 93724 | 0.19 | Why? |
| Eye Infections, Parasitic | 1 | 2018 | 9 | 0.19 | Why? |
| Cryptococcus | 1 | 2018 | 29 | 0.19 | Why? |
| Alginates | 1 | 2018 | 46 | 0.18 | Why? |
| Cavernous Sinus Thrombosis | 1 | 2018 | 13 | 0.18 | Why? |
| Receptors, IgE | 1 | 2018 | 26 | 0.18 | Why? |
| Lipopeptides | 2 | 2017 | 229 | 0.18 | Why? |
| Genome, Fungal | 1 | 2017 | 26 | 0.18 | Why? |
| Real-Time Polymerase Chain Reaction | 1 | 2017 | 11367 | 0.18 | Why? |
| Adolescent | 12 | 2020 | 86841 | 0.18 | Why? |
| Nasal Polyps | 2 | 2018 | 221 | 0.18 | Why? |
| Middle Aged | 23 | 2021 | 270681 | 0.18 | Why? |
| Saccharomyces boulardii | 1 | 2017 | 5 | 0.17 | Why? |
| Hypersensitivity | 2 | 2019 | 1137 | 0.17 | Why? |
| Polymorphism, Restriction Fragment Length | 1 | 2018 | 116 | 0.17 | Why? |
| Soil Microbiology | 1 | 2018 | 63 | 0.17 | Why? |
| Asia | 3 | 2019 | 2399 | 0.17 | Why? |
| Stomach | 1 | 2018 | 141 | 0.17 | Why? |
| Laryngeal Diseases | 1 | 2018 | 60 | 0.17 | Why? |
| Diabetes Complications | 2 | 2021 | 2358 | 0.17 | Why? |
| DNA Transposable Elements | 1 | 2017 | 91 | 0.17 | Why? |
| Aged | 19 | 2021 | 215776 | 0.17 | Why? |
| Biomarkers | 4 | 2019 | 23361 | 0.17 | Why? |
| Cryptococcus neoformans | 1 | 2017 | 71 | 0.17 | Why? |
| Child, Preschool | 8 | 2020 | 36283 | 0.17 | Why? |
| Molecular Typing | 1 | 2018 | 280 | 0.17 | Why? |
| Diagnostic Techniques and Procedures | 1 | 2019 | 265 | 0.17 | Why? |
| Granulomatous Disease, Chronic | 1 | 2017 | 60 | 0.16 | Why? |
| Keratitis | 1 | 2018 | 102 | 0.16 | Why? |
| AIDS-Related Opportunistic Infections | 1 | 2019 | 260 | 0.16 | Why? |
| Immunologic Tests | 1 | 2019 | 445 | 0.16 | Why? |
| United Arab Emirates | 1 | 2019 | 704 | 0.16 | Why? |
| Child | 9 | 2019 | 70012 | 0.16 | Why? |
| Morpholines | 1 | 2018 | 351 | 0.15 | Why? |
| Multigene Family | 1 | 2017 | 377 | 0.15 | Why? |
| Acute-On-Chronic Liver Failure | 1 | 2018 | 237 | 0.15 | Why? |
| Molecular Sequence Annotation | 1 | 2017 | 478 | 0.15 | Why? |
| Societies, Scientific | 1 | 2018 | 414 | 0.14 | Why? |
| Gold | 1 | 2019 | 592 | 0.14 | Why? |
| Prospective Studies | 9 | 2021 | 43301 | 0.14 | Why? |
| Polymerase Chain Reaction | 3 | 2018 | 6740 | 0.14 | Why? |
| Trichosporon | 1 | 2013 | 4 | 0.13 | Why? |
| Drainage | 1 | 2017 | 414 | 0.13 | Why? |
| Trichosporonosis | 1 | 2013 | 10 | 0.13 | Why? |
| Administration, Oral | 2 | 2019 | 2340 | 0.13 | Why? |
| Virulence | 2 | 2019 | 2172 | 0.13 | Why? |
| Bronchiectasis | 1 | 2018 | 312 | 0.13 | Why? |
| Infant | 5 | 2019 | 30274 | 0.13 | Why? |
| Acquired Immunodeficiency Syndrome | 1 | 2019 | 533 | 0.12 | Why? |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2018 | 526 | 0.12 | Why? |
| Risk Factors | 9 | 2021 | 71621 | 0.12 | Why? |
| DNA Primers | 1 | 2017 | 1170 | 0.12 | Why? |
| Case-Control Studies | 4 | 2021 | 17671 | 0.12 | Why? |
| Bronchoalveolar Lavage Fluid | 1 | 2021 | 2309 | 0.12 | Why? |
| Metal Nanoparticles | 1 | 2019 | 771 | 0.12 | Why? |
| DNA | 1 | 2018 | 778 | 0.12 | Why? |
| Intestines | 1 | 2018 | 817 | 0.12 | Why? |
| Ulcer | 1 | 2013 | 128 | 0.11 | Why? |
| Sensitivity and Specificity | 5 | 2019 | 22971 | 0.11 | Why? |
| Leukemia, Myeloid, Acute | 1 | 2018 | 676 | 0.11 | Why? |
| Retrospective Studies | 7 | 2021 | 105322 | 0.11 | Why? |
| Medical Staff, Hospital | 1 | 2021 | 1258 | 0.10 | Why? |
| Respiratory Function Tests | 1 | 2018 | 1755 | 0.10 | Why? |
| Rhinitis | 1 | 2018 | 626 | 0.10 | Why? |
| Drug Monitoring | 1 | 2018 | 1408 | 0.10 | Why? |
| Intensive Care Units | 4 | 2021 | 29594 | 0.10 | Why? |
| Standard of Care | 1 | 2017 | 1297 | 0.10 | Why? |
| ROC Curve | 2 | 2018 | 6024 | 0.10 | Why? |
| Neurosurgical Procedures | 1 | 2020 | 1738 | 0.09 | Why? |
| Public Health Administration | 1 | 2017 | 846 | 0.09 | Why? |
| Age Distribution | 1 | 2018 | 3567 | 0.09 | Why? |
| Prevalence | 6 | 2020 | 25773 | 0.09 | Why? |
| Drug Combinations | 1 | 2018 | 3852 | 0.09 | Why? |
| Cause of Death | 1 | 2021 | 4823 | 0.08 | Why? |
| Wounds and Injuries | 1 | 2019 | 1708 | 0.08 | Why? |
| Multivariate Analysis | 1 | 2017 | 5440 | 0.07 | Why? |
| Survival Analysis | 1 | 2019 | 7592 | 0.07 | Why? |
| Occupational Diseases | 1 | 2021 | 2787 | 0.07 | Why? |
| Laboratories | 1 | 2018 | 2858 | 0.07 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2018 | 3607 | 0.07 | Why? |
| Kidney Failure, Chronic | 1 | 2021 | 3222 | 0.07 | Why? |
| Aged, 80 and over | 5 | 2021 | 88759 | 0.06 | Why? |
| Chronic Disease | 4 | 2018 | 5139 | 0.06 | Why? |
| Developing Countries | 4 | 2021 | 4283 | 0.06 | Why? |
| Coinfection | 2 | 2020 | 6820 | 0.06 | Why? |
| Communicable Diseases, Emerging | 1 | 2017 | 2523 | 0.06 | Why? |
| Immunologic Factors | 1 | 2019 | 4206 | 0.06 | Why? |
| Surgical Procedures, Operative | 1 | 2018 | 2662 | 0.06 | Why? |
| Logistic Models | 1 | 2017 | 9089 | 0.06 | Why? |
| Rhizopus | 1 | 2021 | 32 | 0.06 | Why? |
| Follow-Up Studies | 2 | 2017 | 17020 | 0.06 | Why? |
| Critical Illness | 3 | 2021 | 17281 | 0.05 | Why? |
| Immunoblotting | 1 | 2019 | 180 | 0.05 | Why? |
| Glucuronic Acid | 1 | 2018 | 11 | 0.05 | Why? |
| Hexuronic Acids | 1 | 2018 | 11 | 0.05 | Why? |
| Diabetes Mellitus | 1 | 2021 | 8207 | 0.05 | Why? |
| Cytokines | 2 | 2019 | 15010 | 0.05 | Why? |
| United Kingdom | 1 | 2019 | 18046 | 0.05 | Why? |
| Phylogeny | 1 | 2017 | 13341 | 0.05 | Why? |
| Fatal Outcome | 2 | 2018 | 3438 | 0.05 | Why? |
| Antibiosis | 1 | 2017 | 26 | 0.04 | Why? |
| Tomography, X-Ray Computed | 3 | 2021 | 25144 | 0.04 | Why? |
| Systemic Inflammatory Response Syndrome | 1 | 2018 | 6653 | 0.04 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2021 | 9706 | 0.04 | Why? |
| Proteoglycans | 1 | 2018 | 130 | 0.04 | Why? |
| Blood | 1 | 2018 | 274 | 0.04 | Why? |
| Immunoglobulin G | 2 | 2019 | 21571 | 0.04 | Why? |
| Global Health | 2 | 2018 | 13911 | 0.04 | Why? |
| Interleukin-12 | 1 | 2018 | 156 | 0.04 | Why? |
| Larynx | 1 | 2018 | 126 | 0.04 | Why? |
| Sequence Analysis, DNA | 2 | 2018 | 2830 | 0.04 | Why? |
| International Agencies | 1 | 2018 | 202 | 0.04 | Why? |
| Peritonitis | 1 | 2018 | 217 | 0.04 | Why? |
| Rabbits | 1 | 2019 | 1171 | 0.04 | Why? |
| Nitriles | 1 | 2020 | 1053 | 0.04 | Why? |
| Organizational Policy | 1 | 2021 | 694 | 0.04 | Why? |
| Antibodies, Bacterial | 1 | 2019 | 510 | 0.04 | Why? |
| Comorbidity | 1 | 2020 | 34796 | 0.04 | Why? |
| Infant, Newborn | 1 | 2017 | 23105 | 0.04 | Why? |
| Bone Marrow | 1 | 2018 | 492 | 0.04 | Why? |
| Disease Transmission, Infectious | 1 | 2018 | 9044 | 0.04 | Why? |
| Abdomen | 1 | 2018 | 424 | 0.04 | Why? |
| Age of Onset | 1 | 2017 | 557 | 0.04 | Why? |
| Models, Organizational | 1 | 2021 | 908 | 0.04 | Why? |
| Pyridines | 1 | 2020 | 680 | 0.03 | Why? |
| DNA Mutational Analysis | 1 | 2017 | 581 | 0.03 | Why? |
| Practice Guidelines as Topic | 4 | 2021 | 15421 | 0.03 | Why? |
| Antibiotic Prophylaxis | 1 | 2017 | 399 | 0.03 | Why? |
| DNA, Ribosomal Spacer | 1 | 2013 | 49 | 0.03 | Why? |
| DNA, Ribosomal | 1 | 2013 | 112 | 0.03 | Why? |
| Interleukin-17 | 1 | 2018 | 602 | 0.03 | Why? |
| Infection Control | 2 | 2018 | 23131 | 0.03 | Why? |
| United States | 1 | 2019 | 46150 | 0.03 | Why? |
| Debridement | 1 | 2013 | 172 | 0.03 | Why? |
| Immunophenotyping | 1 | 2017 | 1290 | 0.03 | Why? |
| Nigeria | 1 | 2018 | 2292 | 0.03 | Why? |
| Shock | 1 | 2018 | 1868 | 0.03 | Why? |
| Delivery of Health Care | 1 | 2017 | 15909 | 0.03 | Why? |
| Neoplasms | 1 | 2019 | 17251 | 0.03 | Why? |
| T-Lymphocyte Subsets | 1 | 2018 | 1387 | 0.03 | Why? |
| Hospitalization | 1 | 2020 | 54280 | 0.02 | Why? |
| Drug Resistance, Bacterial | 1 | 2018 | 1414 | 0.02 | Why? |
| Hospitals, University | 1 | 2021 | 4173 | 0.02 | Why? |
| Molecular Sequence Data | 1 | 2013 | 3198 | 0.02 | Why? |
| Software | 1 | 2019 | 2501 | 0.02 | Why? |
| Patient Care | 1 | 2018 | 1664 | 0.02 | Why? |
| Biomedical Research | 2 | 2018 | 5270 | 0.02 | Why? |
| Point-of-Care Testing | 1 | 2019 | 2782 | 0.02 | Why? |
| International Cooperation | 1 | 2019 | 3436 | 0.02 | Why? |
| Phenotype | 1 | 2017 | 4037 | 0.02 | Why? |
| Incidence | 2 | 2018 | 25622 | 0.02 | Why? |
| Risk Assessment | 2 | 2021 | 25439 | 0.02 | Why? |
| Epidemiological Monitoring | 1 | 2018 | 3493 | 0.02 | Why? |
| Anti-Infective Agents | 1 | 2017 | 1766 | 0.02 | Why? |
| Leadership | 1 | 2018 | 2241 | 0.02 | Why? |
| Databases, Factual | 1 | 2019 | 6248 | 0.02 | Why? |
| Computational Biology | 1 | 2019 | 4514 | 0.02 | Why? |
| Adenosine Monophosphate | 1 | 2021 | 5652 | 0.02 | Why? |
| Alanine | 1 | 2021 | 5687 | 0.02 | Why? |
| Predictive Value of Tests | 1 | 2018 | 9537 | 0.02 | Why? |
| Diagnosis, Differential | 1 | 2018 | 7220 | 0.02 | Why? |
| Europe | 1 | 2018 | 12702 | 0.01 | Why? |
| Radiography, Thoracic | 1 | 2018 | 5486 | 0.01 | Why? |
| Socioeconomic Factors | 1 | 2018 | 8495 | 0.01 | Why? |
| Cross-Sectional Studies | 2 | 2018 | 53120 | 0.01 | Why? |
| Mortality | 1 | 2017 | 7132 | 0.01 | Why? |
| Specimen Handling | 1 | 2017 | 6190 | 0.01 | Why? |
| Animals | 2 | 2019 | 78931 | 0.01 | Why? |
| Hospitals | 1 | 2018 | 11793 | 0.01 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2017 | 10649 | 0.01 | Why? |
| Mutation | 1 | 2017 | 12376 | 0.01 | Why? |
| Cross Infection | 1 | 2018 | 8675 | 0.01 | Why? |
| Personal Protective Equipment | 1 | 2021 | 15978 | 0.01 | Why? |
| Prognosis | 1 | 2018 | 32490 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2018 | 43792 | 0.01 | Why? |
| Severity of Illness Index | 1 | 2017 | 48226 | 0.01 | Why? |
| Antiviral Agents | 1 | 2021 | 41703 | 0.01 | Why? |
| Pandemics | 1 | 2021 | 389249 | 0.00 | Why? |